Company Overview and News

 
Buyback offer of Kaveri Seed opens

2018-08-27 thehindubusinessline
The ₹200-crore buyback offer of Kaveri Seed Company opened on Monday and will end on September 7. The company has offered to buy back up to 29.63 lakh shares, or 4.48 per cent of the total paid-up equity, at ₹675 a share. Kaveri Seed had set August 3 as the record date for shareholders to participate in the buyback, which is through tender route on a proportionate basis. On Monday, just 1,028 shares (0.
570002 LICHSGFIN KSCL FRLDVR FRL 523574 LHFLY 532899 500253

 
D-Street Buzz: Metals shine led by Hindustan Zinc, JSW Steel; Pfizer zooms 12%, hits fresh 52-week high

2018-08-24 moneycontrol
The Indian market continues to trade in the red this Friday afternoon with the Nifty down 24 points and trading at 11,558. The Sensex on the other hand is trading lower by 79 points and is trading at 38,257.
AMKD 500325 UBL 532715 532478 CADILAHC 532321 532483 KSCL BJJQY RLNIY EXIDEIND AXB YYBKY JSWSTEEL CNRYY AXBA EXQDY BAJFINANCE BATAINDIA CANBK 507458 500188 HINDZINC 500228 RELIANCE AMTEKAUTO HNDZY 532899 532215 GITANJALI AXISBANK RIGD 500034 YESBANK UBNC IBN UBHOLDINGS 532648 UNBWY CDLYY 539207 AXBKY GTJLY ICICIBANK 532174 520077 500086 500043 MANPASAND

 
D-Street Buzz: Bank, pharma stocks fall with ICICI Bank Sun Pharma down 2%; SREI Infra zooms 10%

2018-08-24 moneycontrol
The Indian market have turned negative this Friday afternoon with the Nifty down 32 points and trading at 11,550. The Sensex on the other hand is trading lower by 109 points and is trading at 38,227.
GRASIM AMKD 500325 UBL 532715 532478 CADILAHC 532321 534816 KSCL BJJQY RLNIY SBAZ EXIDEIND GRSJY AXB YYBKY AXBA EXQDY BAJFINANCE BATAINDIA 500300 507458 BHRYY RELIANCE IDBI AMTEKAUTO 532899 532215 GITANJALI AXISBANK RIGD INFRATEL 500034 YESBANK UBNC 500116 IBN UBHOLDINGS 532648 UNBWY CDLYY AXBKY GTJLY GRSXY ICICIBANK 532174 520077 500086 500043

4
D-Street Buzz: Nifty Pharma outperforms led by Dr Reddy#39;s Labs; MGL most active, falls 6%, Prataap Snacks zooms 17%

2018-08-23 moneycontrol
The Indian benchmark indices are trading on a positive note this Thursday morning with the Nifty up 17 points and trading at 11,588. The Sensex on the other hand is up 71 points and is trading at 38,356.
500825 AMKD ADANIENT AUROPHARMA BRTQY 532715 AMTEKAUTO 532218 MARKSANS 532899 BHRQY 512599 532215 GITANJALI SOUTHBANK 532343 MOZTY AXISBANK KSCL 500570 BHARTIARTL BRITANNIA TATAMOTORS 524404 517354 ANNRY HVLQY TVSMOTOR AXB 524804 517334 AXBKY 532454 GTJLY AXBA BATAINDIA MOTHERSUMI ARBQY HAVELLS 520077 500043 TTM

5
An evening walk down Dalal Street: MSP price hike gives a push to Indian markets; Sensex rallies over 250 points

2018-07-04 moneycontrol - 1
The S&P BSE Sensex rallied over 200 points on Wednesday despite negative global cues. The Nifty50 reclaimed 10,700 levels and closed above its short-term moving averages such as 5-EMA, 13-EMA, as well as 50-EMA which is a bullish sign.
UNICHEMLAB KOHINOOR 539275 532899 BHRQY SRTRANSFIN 511218 532454 512559 532783 506690 KSCL SRRQY MSL 500570 BHARTIARTL TATAMOTORS DAAWAT TTM

 
Agri stocks soar up to 10% after government hikes minimum support price of kharif crops

2018-07-04 moneycontrol
Shares of agriculture-related stocks rose on Wednesday as investors were upbeat on government's decision to hike minimum support price.
512559 532783 KOHINOOR 539275 KSCL MSL 532899 DAAWAT

8
Will compulsory delivery impact F&O trading?

2018-06-29 thehindubusinessline
KS Badri Narayanan Be prepared to have enough money in your account if you want to trade in the 46 F&O stocks that have been moved to the compulsory delivery category by the NSE starting July. This follows the SEBI diktat in March to align the cash and derivative segments of the market, through physical settlement for all stock derivatives in a phased and calibrated manner. To start with, the NSE has initiated compulsory delivery in 46 stocks.
SRI 532939 SREINFRA GODREJIND 533096 UBL IDBI 532899 532712 532478 533106 JUSTDIAL GRANULES 535648 RCOM OIL 532482 KSCL DCBBANK RPOWER SIFLY 523756 ALNSE 500116 UBHOLDINGS 535322 SRIA UNBWY REPCOHOME 532772 ADANIPOWER 507458 500164 JSTQY

1
Monsanto rival Kaveri Seed seeks bigger pie of Indian seed market

2018-06-12 livemint
Mumbai: Kaveri Seed Co., which competes with Monsanto Co. to sell hybrid seeds in India, is seeking a bigger share of the food crop market to reduce dependence on cotton seed, its breadwinner. The company gets about 60% of revenue from cotton seed sales and the remainder from vegetable seeds and grains including paddy and corn. It aims to reverse the proportion in three years, enticed by profit margins that are almost double that of the cotton segment, executive director C.
KSCL MON 532899

1
Kaveri Seed: Eyes on results, buyback

2018-05-23 thehindubusinessline
The board of Kaveri Seed Company will meet on Thursday to consider the audited financial results for the quarter/year ended March 31, 2018. The board will also consider a proposal for buyback of the equity shares of the company. If the proposal is approved by the board, shareholders would be keen to know the price, issue size and mode of buyback (whether open market purchase or through tender route).
KSCL 532899 SBAZ

 
Ashoka Pte sells 6.60 lakh shares of Kaveri Seed Company

2018-05-19 moneycontrol
On May 18, 2018 Ashoka PTE sold 6,60,815 shares of Kaveri Seed Company at Rs 500.13 on the NSE.
KSCL 532899

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...